Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLSFree Report) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

RGLS has been the subject of several other reports. Canaccord Genuity Group decreased their price objective on shares of Regulus Therapeutics from $12.00 to $11.00 and set a buy rating for the company in a report on Tuesday, March 19th. Wells Fargo & Company increased their price objective on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an equal weight rating in a research note on Wednesday, March 13th. SVB Leerink assumed coverage on Regulus Therapeutics in a research note on Monday, March 18th. They set an outperform rating and a $6.00 price target for the company. HC Wainwright reaffirmed a buy rating and set a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday, March 25th. Finally, Leerink Partnrs reissued an outperform rating on shares of Regulus Therapeutics in a report on Monday, March 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $7.25.

Read Our Latest Research Report on Regulus Therapeutics

Regulus Therapeutics Price Performance

RGLS opened at $2.88 on Friday. The stock has a market capitalization of $188.52 million, a PE ratio of -1.81 and a beta of 1.45. The firm’s fifty day moving average price is $1.75 and its 200 day moving average price is $1.48. Regulus Therapeutics has a 12-month low of $0.78 and a 12-month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLSGet Free Report) last issued its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.40). On average, equities research analysts forecast that Regulus Therapeutics will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGLS. Exome Asset Management LLC bought a new stake in shares of Regulus Therapeutics in the 4th quarter worth approximately $228,000. Victory Capital Management Inc. increased its stake in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after buying an additional 38,529 shares during the period. FMR LLC increased its stake in shares of Regulus Therapeutics by 32.4% in the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares during the period. Prelude Capital Management LLC acquired a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at $60,000. Finally, Renaissance Technologies LLC grew its stake in shares of Regulus Therapeutics by 18.8% during the second quarter. Renaissance Technologies LLC now owns 46,100 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 7,300 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

(Get Free Report)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Featured Stories

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.